The risk of shorter fasting time for pediatric deep sedation

Mathew Clark1, Esma Birisci2, Jordan E Anderson3

  • 1Division of Critical Care Medicine, St. Louis University, St. Louis, MO, USA.

Insights

Shorter fasting times (4-6 hours) are safe for pediatric procedural sedation and analgesia (PSA) in healthy children undergoing elective procedures outside the operating room, showing no increased complication risks compared to longer fasting periods.

Area of Science:

  • Pediatric Critical Care Medicine
  • Anesthesiology
  • Sedation Management

Background:

  • Current American Academy of Pediatrics guidelines recommend prolonged fasting before pediatric procedural sedation and analgesia (PSA).
  • PSA is increasingly utilized for children outside the operating theater by specialized providers, often without airway manipulation.
  • Investigated the safety of shorter fasting intervals versus guideline-compliant longer intervals for PSA.

Purpose of the Study:

  • To determine the association between fasting duration and sedation-related complications in pediatric patients.
  • To compare complication rates between shorter (4-6 hours) and longer (>6 hours) fasting times for PSA.

Main Methods:

  • Prospective observational study of 2487 children (2-18 years) with ASA physical status I or II undergoing deep sedation.
  • Patients received sedation for elective procedures like imaging, EEG, and minor surgeries, performed by pediatric critical care providers.
  • Subjects were grouped by fasting time: 4-6 hours versus >6 hours; complication rates were compared.

Main Results:

  • 40.5% of subjects (1007) fasted for 4-6 hours; 59.5% (1480) fasted for >6 hours.
  • No statistically significant differences in complication rates were observed between the shorter and longer fasting groups.
  • Complications analyzed included those related to sedation during elective procedures in healthy children.

Conclusions:

  • Shorter fasting times (4-6 hours) appear safe for healthy pediatric patients undergoing elective procedures outside the OR.
  • Findings suggest current prolonged fasting guidelines may be unnecessarily restrictive for specific pediatric sedation scenarios.
  • This study supports the safety of modified fasting protocols when performed by trained providers without airway manipulation in low-risk children.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
626
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
861
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
414
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
673
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
309